Latham & Watkins Advises on Monte Rosa Therapeutics’ US$300 Million Underwritten Public Offering

Monte Rosa Therapeutics, Inc. (Monte Rosa) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, has announced the pricing of an underwritten public offering of 11,125,000 shares of its common stock at a public offering price of US$24 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,375,000 shares of common stock at a public offering price of US$23.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the US$0.0001 per share exercise price for each pre-funded warrant. Monte Rosa also granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Monte Rosa from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately US$300 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares and pre-funded warrants in the offering are to be sold by Monte Rosa. The offering is expected to close on or about January 12, 2026, subject to satisfaction of customary closing conditions.

Latham & Watkins LLP represents the underwriters in the offering with a Capital Markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with associates Zoey Wu, Yulong Li, and Michelle Zheleznyakov.*

*Admitted to practice in England and Wales.